抑制肺癌新生血管及其临床应用的研究进展  

Research progress in inhibiting neovascularization of lung cancer and its clinical application

作　　者：张瑞连 张卿[2] ZHANG Rui-lian;ZHANG Qing(Graduate School of Inner Mongolia Medical University,Inner Mongolia Autonomous Region,Hohhot 010010,China;Department of Respiratory Medicine,Affiliated Hospital of Inner Mongolia Medical University,Inner MongoliaAutonomous Region,Hohhot 010010,China)

机构地区：[1]内蒙古医科大学研究生院,内蒙古呼和浩特010010 [2]内蒙古医科大学附属医院呼吸内科,内蒙古呼和浩特010010

出　　处：《中国当代医药》2018年第26期36-38,共3页China Modern Medicine

基　　金：内蒙古医科大学附属医院重大科研资助项目(NYF Y ZD 2012001)

摘　　要：血管新生是影响肿瘤的发生、侵袭和转移等恶性生物学行为的重要因素之一,阻断肿瘤细胞的血供,使细胞处于缺氧及营养物质缺少的状态,是抑制肿瘤生长增殖的有效手段,以肿瘤血管生成为靶点的靶向治疗己成为非小细胞肺癌(NSCLC)的研究热点,然而,肿瘤的血管生成极其复杂,单个靶点阻断治疗并不能解决根本问题,未来抗血管治疗的方向将集中于多靶点、多部位的联合阻断用药方式。本文对几种与肿瘤血管生成有关调节因子的作用及其临床应用进行了综述,旨在为肺癌临床研究提供一定参考。Angiogenesis can seriously affect the occurrence and development of tumors. In recent years, with the development of molecular biology, targeting angiogenesis has become a research hotspot for the treatment of non-small cell lung cancer（NSCLC）. Blocking the blood supply of tumor cells, making the cells in a state of hypoxia and lack of nutrients, is an effective means to inhibit the growth and proliferation of tumors. Targeting tumor angiogenesis as a target has become a research hotspot, however, the Angiogenesis is extremely complex, and single target blocking therapy often does not solve the underlying problem. Future anti-vascular therapies will focus on multi-target combined blockade. This article reviews the role of several regulatory factors related to tumor angiogenesis and their clinical applications, aiming to provide a reference for the clinical research of lung cancer.

关 键 词：非小细胞肺癌 血管新生 表皮生长因子受体酪氨酸激酶抑制剂 环氧化酶-2抑制剂 

分 类 号：R73[医药卫生—肿瘤]